MAUI Imaging是一家成立15年的医疗初创公司，由一对父子于2006年在硅谷的车库中创立。该公司致力于开发能够穿透传统超声设备限制的成像技术，特别是能够看穿骨骼、气体、脂肪、仪器和植入物等障碍物。此轮融资1400万美元将用于进一步开发这项技术，旨在加速诊断和治疗过程，尤其是在创伤评估领域，可供训练较少的医护人员使用。该技术有望为AI健康工具提供大量数据，并已获得美国国防部的合同支持。

💡 **突破性超声成像技术**：MAUI Imaging正在开发一种能够穿透传统超声成像限制的系统，可以看见骨骼、气体、脂肪、器械和植入物等障碍物，有望加速诊断和治疗，尤其是在创伤场景下，减少对CT或MRI扫描的依赖。

👨‍👦 **父子创业与技术沉淀**：公司由一对父子于2006年在硅谷车库创立，创始人之一Don Specht曾参与太空望远镜的开发，将相关技术应用于人体成像。公司CEO David Specht表示，技术的实现得益于“摩尔定律的追赶”，表明其技术研发具有前瞻性和长期积累。

🛡️ **军方认可与应用前景**：MAUI Imaging已获得美国国防部的合同，以研究其在野战创伤评估中的应用。该技术便携且易于训练操作，能将决策点前移，解决前线医生资源不足的问题。军方对其技术的潜力给予了高度认可。

📈 **融资与市场布局**：MAUI Imaging已累计融资约4000万美元。最新一轮的1400万美元Series D融资由超声设备公司Acertara领投，后者获得了该系统的独家分销权。该系统的平均售价为85,000美元，且公司拥有160项专利。

🔬 **监管与未来发展**：虽然该设备已获得FDA对传统超声用途的许可，但MAUI Imaging正利用与军方的临床试验数据，寻求关于穿透障碍物成像能力的进一步审批，以期在未来获得更广泛的应用和市场认可。

A father-son duo founded MAUI Imaging out of their Silicon Valley garage in 2006.The ultrasound startup has raised about $40 million to date.It aims to expedite diagnoses with imaging that can see beyond traditional devices.

Medical startup MAUI Imaging announced Tuesday it has raised $14 million in Series D funding to develop ultrasound technology that can glimpse beyond traditional devices.

While ultrasounds are mostly used for soft tissue, MAUI says it's developing a system to see through and around traditional barriers like bone, gas, fat, instruments, and implants. The company aims to expedite diagnosis and treatment, particularly in trauma scenarios, given that this kind of imaging typically requires CT or MRI scans.

A father-son duo founded MAUI — an acronym for Multiple Aperture Ultrasound Insonification — out of their Silicon Valley garage in 2006.

The late Don Specht started developing the technology while building space telescopes at Lockheed Martin, and sought — alongside his son David, a former Air Force flyer-turned-entrepreneur who serves as MAUI's CEO — to apply it to the human body.

"We had to wait for Moore's Law to catch up," David Specht said of MAUI's long developmental road.

The company emerged from stealth in August 2024 with a $4 million Department of Defense contract to study its applications in the field. The military is particularly interested in using the portable system for trauma assessment by corpsmen or medics with minimal training, Specht said.

"They're trying to move the decision-making point as far forward as possible because they don't have enough doctors," Specht said.

He added that MAUI's imaging results in a massive trove of data that could be useful for AI health tools.

MAUI counts eight employees and eight consultants, and it has raised roughly $40 million to date.

The Series D included equity funding and was led by ultrasound device company Acertara, which now has exclusive distribution rights to the system. The average sales price for the system is $85,000, plus maintenance costs, Specht said.

While the FDA has cleared the device for traditional ultrasound uses, MAUI — which has 160 patents — will use data gleaned from its clinical trials with the military as it seeks clearance to make claims about seeing through and around obstructions.

Here's a look at the pitch deck MAUI Imaging used to raise its $14 million Series D. Some slides and details have been redacted in order to share the deck publicly.